Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.

Cha Len Lee,Mattia Cremona,Angela Farrelly,Julie A Workman,Sean Kennedy,Razia Aslam,Aoife Carr,Stephen Madden,Brian O'Neill,Bryan T Hennessy,Sinead Toomey

Cancer biology & therapy（2023）

引用 0|浏览8

暂无评分

摘要

This study shows that the combination of Palbociclib and Gedatolisib has synergistic anti-proliferative effects in both wild-type and mutated CRC cell lines. Separately, the phosphorylation of S6rp may be a promising biomarker of responsiveness to this combination.

查看译文

关键词

mek inhibitor,colorectal cancer,pi3k

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要